[go: up one dir, main page]

NO20006113L - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
NO20006113L
NO20006113L NO20006113A NO20006113A NO20006113L NO 20006113 L NO20006113 L NO 20006113L NO 20006113 A NO20006113 A NO 20006113A NO 20006113 A NO20006113 A NO 20006113A NO 20006113 L NO20006113 L NO 20006113L
Authority
NO
Norway
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
NO20006113A
Other languages
Norwegian (no)
Other versions
NO20006113D0 (en
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20006113D0 publication Critical patent/NO20006113D0/en
Publication of NO20006113L publication Critical patent/NO20006113L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20006113A 1998-06-02 2000-12-01 Use of cyclosporins in the treatment of inflammatory autoimmune diseases NO20006113L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
NO20006113D0 NO20006113D0 (en) 2000-12-01
NO20006113L true NO20006113L (en) 2001-01-25

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006113A NO20006113L (en) 1998-06-02 2000-12-01 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (en)
JP (2) JP4523154B2 (en)
KR (1) KR20010043969A (en)
CN (1) CN1304315A (en)
AU (1) AU750422B2 (en)
BR (1) BR9910860A (en)
CA (1) CA2333315A1 (en)
GB (1) GB9811854D0 (en)
HU (1) HUP0102142A3 (en)
ID (1) ID27576A (en)
IL (1) IL139589A0 (en)
NO (1) NO20006113L (en)
PL (1) PL344451A1 (en)
SK (1) SK18142000A3 (en)
TW (2) TWI250021B (en)
WO (1) WO1999062540A1 (en)
ZA (1) ZA200006464B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297217T1 (en) 1999-10-27 2005-06-15 Alexandra Lucas COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION
AU2001291579B2 (en) * 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN1964735A (en) * 2004-04-08 2007-05-16 诺瓦提斯公司 Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury
RU2394589C2 (en) 2004-07-14 2010-07-20 Новартис Аг Application of cyclosporine and pegylated interferon combination for hepatitis (hcv) treatment
JP2008514702A (en) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Novel cyclosporine analogues and their pharmaceutical use
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
CN101056648B (en) * 2004-10-01 2012-08-15 德比奥法姆股份有限公司 Application of [d-meala]3- [etval]4 cyclosporin in treating hepatitis c infection and medicine composition containing [d-meala]3- [etval]4 cyclosporin
JP2008515886A (en) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド Cyclosporine alkynes and their usefulness as medical drugs
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
BRPI0519345A2 (en) 2004-12-23 2009-01-20 Novartis Ag hcv treatment composition
CA2587586A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
US20090221598A1 (en) 2005-06-17 2009-09-03 Kai Lin Use of Sanglifehrin in HCV
JP2007112775A (en) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine Use of cyclosporines in the treatment of cytomegalovirus infection
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2011070364A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
JP2015532277A (en) 2012-09-29 2015-11-09 ノバルティス アーゲー Cyclic peptides and their use as pharmaceuticals
US20140212381A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124459T3 (en) * 1990-11-02 2001-05-31 Novartis Ag, Basel Cyclosporine
AR006514A1 (en) * 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations

Also Published As

Publication number Publication date
AU750422B2 (en) 2002-07-18
AU4372499A (en) 1999-12-20
KR20010043969A (en) 2001-05-25
TWI250022B (en) 2006-03-01
WO1999062540A1 (en) 1999-12-09
HUP0102142A3 (en) 2001-12-28
JP2010059177A (en) 2010-03-18
JP4523154B2 (en) 2010-08-11
JP2002516873A (en) 2002-06-11
TW200522975A (en) 2005-07-16
PL344451A1 (en) 2001-11-05
BR9910860A (en) 2001-03-06
CA2333315A1 (en) 1999-12-09
CN1304315A (en) 2001-07-18
ZA200006464B (en) 2002-03-11
HUP0102142A2 (en) 2001-11-28
EP1082130A1 (en) 2001-03-14
NO20006113D0 (en) 2000-12-01
TWI250021B (en) 2006-03-01
SK18142000A3 (en) 2001-06-11
ID27576A (en) 2001-04-12
GB9811854D0 (en) 1998-07-29
IL139589A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
NO20006113L (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
NO995095L (en) Substituted imidazoles useful in the treatment of inflammatory diseases
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
DK1047428T3 (en) Use of morpholinol in the treatment of sexual disorders
EE03512B1 (en) Epinastine for use in the treatment of pain
EE05507B1 (en) Use of rosuvastatin ZD4522) in the treatment of heterosgococcal family h percolesterolemia
PT946175E (en) USE OF A COMBINATION OF H +, K + -ATPASE AND GLUCOCORTICIOD INHIBITORS IN THE TREATMENT OF NASA POLLS
NO20031525L (en) Chemokine mutants in the treatment of multiple sclerosis
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
FI964809A0 (en) In the case of use of the processing unit
EP1027007A4 (en) DENTAL TREATMENT TECHNIQUES
NO965247D0 (en) Use of cross-linked hemoglobin in the treatment of subarakuoid hemorrhage
NO20010044L (en) Use of texaphyrins in macrophage-mediated diseases
DE59701536D1 (en) LOW-FIBRILLATION SHAPED BODY
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
NO20030762L (en) Improved specificity in the treatment of diseases
ID28817A (en) USE OF TETRAHIDROPIRIDIN (OR 4-HIDROPIPERIDIN) -BUTILAZOL DRUGS IN THE MAKING OF DRUGS FOR PAIN TREATMENT
DK5198A (en) Endoscopic Dormia foreign body extractor
NO20032054D0 (en) Fatty acid analogues for the treatment of inflammatory disorders and autoimmune disorders
IT1311913B1 (en) USE OF 6-METHYLMERCAPTOPURIN RIBOSIDE IN OPHTHALMOLOGICAL COMPOSITIONS.
BR9604756A (en) Medical bathtub
BR7601412U (en) Appliance applicable in the treatment of grain flow in general
UA3289S (en) MAP OF ZONES OF INFORMATION-WAVE INTERACTIONS ON THE HUMAN BODY
ITSA960002A0 (en) ORGANIC MASSAGER HELMET - STIMULATING WITH ANTITROPHIC ACTION OF THE FRONTAL - PARIETAL AREA OF THE SCALP
BR7603225U (en) Constructive arrangement applied in the manufacture of portable chair

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application